

**RECORDATI: PUBLIC DISCLOSURE**

Milan, 4 March 2019 – Please be informed that, today, the Company made available to the public the following documents as approved by the Board of Directors on 28<sup>th</sup> February 2019: (i) the financial statements at, and for the year ended, 31 December 2018, (ii) the 2018 corporate governance report and ownership structure, (iii) the 2018 consolidated non-financial information disclosure pursuant to Legislative Decree n. 254 dated 30 December 2016, and (iv) the entire notice of call of the Ordinary Shareholders' Meeting (11 April 2019 in a single call at 10.00 a.m.).

The mentioned documents are available at the Company's registered office and published on the Company's website ([www.recordati.it](http://www.recordati.it)) and on the "1info" storage mechanism ([www.1info.it](http://www.1info.it)).

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2018 was € 1,352.2 million, operating income was € 442.2 million and net income was € 312.4 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

Investor Relations

Marianne Tatschke  
(39)0248787393  
e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

Media Relations

Studio Noris Morano  
(39)0276004736, (39)0276004745  
e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Sede Legale  
VIA M. CIVITALI, 1  
20148 MILANO, ITALIA  
TEL. (39) 0248787.1  
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.  
REG. IMP. MILANO, MONZA, BRIANZA E LODI N. 00748210150  
CODICE FISCALE/P.IVA 007482210150  
R.E.A. MILANO N. 401832

Società Soggetta all'attività di Direzione e Coordinamento di Rossini Luxembourg S.à r.l